Moderna initiates phase III study of RSV vaccine

The US-based biotech company now enters the last phase with its vaccine candidate against RSV.

Photo: Dado Ruvic/REUTERS / X02714

US-based Moderna is entering the final sprint in the race to have the first vaccine against respiratory syncytial virus (RSV), as reported by Danish business daily Børsen in connection with a company press release, which declared that two successful phase II trials have opened the pathway to a phase III study.

Other suitors for the potential billion-dollar market include Johnson & Johnson, Pfizer, Glaxosmithkline and Bavarian Nordic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs